Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides

https://doi.org/10.1016/j.bmcl.2017.05.014Get rights and content

Abstract

This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The SAR to address potency, clearance, subtype selectivity, CNS exposure, and P-gp efflux are described. This work culminated in the discovery of VU6000918, which demonstrated robust efficacy in a rat amphetamine-induced hyperlocomotion reversal model at a minimum efficacious dose of 0.3 mg/kg.

Section snippets

Acknowledgments

The authors would like to thank NIH (U01MH087965, Vanderbilt, NCDDG). We also thank William K. Warren, Jr. and the William K. Warren Foundation who funded the William K Warren, Jr. Chair in Medicine (to C.W.L.).

References (24)

  • U. Le et al.

    Bioorg Med Chem Lett

    (2013)
  • J.M. Salovich et al.

    Bioorg Med Chem Lett

    (2012)
  • E. Smith et al.

    J Biomol Screening

    (2015)
  • M.R. Wood et al.

    Bioorg Med Chem Lett

    (2016)
  • M.R. Wood et al.

    Bioorg Med Chem Lett

    (2016)
  • M.R. Wood et al.

    Bioorg Med Chem Lett

    (2017)
  • J.P. Wolfe et al.

    Acc Chem Res

    (1998)
  • W.Y. Chan et al.

    Proc Natl Acad Sci USA

    (2008)
  • K. Leach et al.

    Neuropsychopharmacology

    (2010)
  • A. Brady et al.

    J Pharm Exp Ther

    (2008)
  • N.E. Byun et al.

    Neuropsychopharmacology

    (2014)
  • M. Farrell et al.

    Neuropsychopharmacology

    (2010)
  • Cited by (16)

    • Structure–activity relationship of pyrazol-4-yl-pyridine derivatives and identification of a radiofluorinated probe for imaging the muscarinic acetylcholine receptor M<inf>4</inf>

      2023, Acta Pharmaceutica Sinica B
      Citation Excerpt :

      Notwithstanding the high affinity and selectivity of VU010010 for M4 receptors, its further development was plagued by solubility issues and P-glycoprotein (P-gp) efflux in vivo29. Other derivatives of the same series include, but are not limited to, VU0152099 and VU0152100 (ML108)30–33, VU046715434,35, VU0409524 (ML293)36, VU600091837, VU044808838, VU602841839 as well as VU0467485 (AZ13713945)40 (Fig. 1), but clinical trials with these compounds have not been reported to date. Indeed, M4-selective targeted therapy is far from routine clinical use and the majority of reported ligands were plagued by inappropriate bioavailability and CNS exposure, high P-gp efflux liability, species variability, and poor metabolic stability or selectivity for M4.

    • Four-Membered Ring Systems

      2018, Progress in Heterocyclic Chemistry
      Citation Excerpt :

      Image Continued chemical optimization of a novel series of muscarinic acetylcholine receptor (M4) positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety 8 is detailed (17BMCL2990). A scaffold hopping exercise identified a novel 2,4-dimethylquinoline-6-carboxamide core in 9 that possesses M4 PAM activity and good central nervous system penetration without an amino moiety (17BMCL4999).

    View all citing articles on Scopus
    View full text